Report Contents
Jump to any section in the series
Report Contents
Jump to any section in the series
- Introduction →
- Definitions And Scope →
- Executive Summary →
- Key Trends →
- Market Value →
- Legislation and Regulation →
- Consumer Attitudes →
- Healthcare Providers’ Attitudes →
- Spotlight On Health →
- Psychedelics – Timeline of Key Developments →
- Countries to Watch →
- Psychedelic Profiles →
- Key Psychedelics Deep Dive →
- Other Psychedelics of Note →
- Psychedelics as Medicine: Potential Therapies →
- Psychedelics and Technology →
- Psychedelics Per Country →
- Psychedelics and The Law →
- Patents and Intellectual Property →
- Therapy Practitioners →
- Psychedelic Research →
- Glossary →
No matches. Try a different keyword.
Psychedelic Profiles
The tables below provide a high-level overview of health conditions and psychedelic substances with potential to treat them.
List of health conditions and the psychedelic substances with the potential to treat them
| Health condition | Psilocybin | LSD | MDMA | Ketamine | Ibogaine | Ayahuasca | DMT/5-MeO-DMT | Mescaline/Peyote | Salvinorin A/Salvia |
|---|---|---|---|---|---|---|---|---|---|
| Depression (MDD) (TRD) | |||||||||
| Bipolar disorder | |||||||||
| Suicidal ideation | |||||||||
| Anxiety | |||||||||
| Autism (Social Anxiety) | |||||||||
| PTSD | |||||||||
| Eating disorders | |||||||||
| Alcohol use disorder |
Note: This is an indicative list for illustrative purposes only and should not be regarded as exhaustive.
Source: Blossom/ClinicalTrials.gov
Source: Blossom/ClinicalTrials.gov
Additional conditions referenced in research and development
| Health condition | Psilocybin | LSD | MDMA | Ketamine | Ibogaine | Ayahuasca | DMT/5-MeO-DMT | Mescaline/Peyote | Salvinorin A/Salvia |
|---|---|---|---|---|---|---|---|---|---|
| Opioid use disorder | |||||||||
| Chronic pain | |||||||||
| ADHD | |||||||||
| Cluster headaches | |||||||||
| Stroke | |||||||||
| OCD | |||||||||
| Inflammation |
Note: This is an indicative list for illustrative purposes only and should not be regarded as exhaustive.
Source: Blossom/ClinicalTrials.gov
Source: Blossom/ClinicalTrials.gov
